Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases

Cytometry Part B - Clinical Cytometry

Volumn 72, Issue 5, 2007, Pages 363-370

  Klabusay, Martin ^a,c   Sukova, Vera ^a   Coupek, Petr ^b   Brychtova, Yvona ^a   Mayer, Jiri ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b CZECH GEOLOGICAL SURVEY   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Alemtuzumab; Antibody binding capacity; CD34+ cells; CD52; Chronic lymphocytic leukemia; MESF; Non Hodgkin's lymphoma; Quantitative flow cytometry

Indexed keywords

ALEMTUZUMAB; CD34 ANTIGEN; CD52 ANTIGEN; FLUOROCHROME; BIOLOGICAL MARKER; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR MARKER;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MEASUREMENT; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUANTITATIVE FLUORESCENCE CYTOMETRY; TUMOR CELL; ADULT; AGED; B CELL LEUKEMIA; BIOSYNTHESIS; BLOOD; CHRONIC DISEASE; COMPARATIVE STUDY; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD34; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CHRONIC DISEASE; FEMALE; FLOW CYTOMETRY; GLYCOPROTEINS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, B-CELL; LYMPHOCYTE ACTIVATION; LYMPHOMA, MANTLE-CELL; LYMPHOMA, SMALL LYMPHOCYTIC; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 35748968833     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20181     Document Type: Article

References (38)

1. Nadler LM, Stashenko P, Hardy R, Kaplan WD, Button LN, Kufe DW, Antman KH, Schlossman SF. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980;40:3147-3154.
2. Dearden CE, Matutes E, Cazin B, Tjonnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001;98:1721-1726.
3. Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, Schetelig J, Selpelt G, Osterborg A. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy- refractory peripheral T-cell lymphomas. Blood 2004;103:2920-2924.
4. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 2002;99:554-561.
5. Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Santabarbara P, Wacker B, Brettman L. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002;20:3891-3897.
6. Rawstron AC, Kennedy B, Moreton P, Dickinson AJ, Cullen MJ, Richards SJ, Jack AS, Hillmen P. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood 2004;103:2027-2031.
7. Rosenblum MD, LaBelle JL, Chang CC, Margolis DA, Schauer DW, Vesole DH. Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia. Blood. 2004;103:1969-1971.
8. Cheung WW, Hwang GY, Tse E, Kwong YL. Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab. Haematologica 2006;91(5 Suppl):ECR13.
9. Hale G, Cobbold SP, Waldmann H. T cell depletion with Campath-1 in allogeneic bone marrow transplantation. Transplantation 1988;45:753-759.
10. Multani PS, Grossbard ML. Monoclonal antibody-based therapies for hematologic malignancies. J Clin Oncol 1998;16:3691-3710.
11. Novitzky N, Thomas V, Hale G, Waldmann H. Campath-1 Abs 'in the bag' for hematological malignancies: The Cape Town experience. Cytotherapy 2004;6:172-181.
12. Giralt S. The role of alemtuzumab in nonmyeloablative hematopoietic transplantation. Semin Oncol 2006;33:S36-S43.
13. Xia MQ, Hale G, Lifely MR, Ferguson MA, Campbell D, Packman L, Waldmann H. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993;293:633-640.
14. Treumann A, Lifely MR, Schneider P, Ferguson MAJ. Primary sructure of CD52. J Biol Chem 1995;270:6088-6099.
15. Hale G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990;35:118-27.
16. Eisner J, Höchstetter R, Spiekermann K, Kapp A. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 1996;88:4684-4693.
17. Gilleece MH, Dexter TM. Effect of CAMPATH-1H antibody on human haemapoietic progenitors in vitro. Blood 1993;82:807-812.
18. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988;332:323-327.
19. Mone AP, Cheney C, Banks AL, Tridandapani S, Mehter N, Guster S, Lin T, Eisenbeis CF, Young DC, Byrd JC. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 2006;20:272-279.
20. Osterborg A, Dyer MJ, Bunjes D, PanglalisBastion Y, Catovsky D, Mellstedt H. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia.European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997;15:1567-1574.
21. Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJS, Catovsky D. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 1997;96:617-619.
22. Pawson R, Dyer MJ, Barge R, Matutes E, Thornton PD, Emmett E, Kluin-Nelemans JC, Fibbe WF, Willemze R, Catovsky D. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997;15:2667-2672.
23. Owen RG, Hillmen P, Rawstron AC. CD52 expression in Waldenstrom's macroglobulinemia: Implications for alemtuzumab therapy and response assessment. Clin Lymphoma 2005;5:278-281.
24. Kumar S, Kimlinger TK, Lust JA, Donovan K, Witzig TE. Expression of CD52 on plasma cells in plasma cell proliferative disorders. Blood 2003;102:1075-1077.
25. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998;22:185-191.
26. Sung C, Shockley TR, Morrison PF, Dvorak HF, Yarmush ML, Dedrick RL. Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors. Cancer Res 1992;52:377-384.
27. Henderson LO, Marti GE, Gaigalas A, Hannon WH, Vogt RF Jr. Terminology and nomenclature for standardization in quantitative fluorescence cytometry. Cytometry 1998;33:97-105.
28. Hale G, Hoang T, Prospero T, Watt SM, Waldmann H. Removal of T cells from bone marrow for transplantation: Comparison of rat monoclonal anti-lymphocyte antibodies of different isotypes. Mol Biol Med 1983,1:305-319.
29. Dyer MJ. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 1999;26:52-57.
30. Olweus J, Lund-Johansen F, Terstappen LW. Expression of cell surface markers during differentiation of CD34+, CD38-/lo fetal and adult bone marrow cells. Immunomethods 1994;5:179-188.
31. Zheng C, Li L, Haak M, Brors B, Frank O, Giehl M, Fabarius A, Schatz M, Weisser A, Lorentz C, Gretz N, Hehlmann R, Hochhaus A, Seifarth W. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 2006;20:1028-1034.
32. Rossmann ED, Lundin J, Lenkei R, Mellstedt H, Österborg A. Variability in B-cell antigen expression: Implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J 2001;2:300-306.
33. Bass AJ, Gong J, Nelson R, Rizzieri D. CD52 expression in mantle cell lymphoma. Leuk Lymphoma 2002;43:339-342.
34. Quigley MM, Bethel KJ, Sharpe RW, Saven A. CD52 expression in hairy cell leukemia. Am J Hematol 2003;74:227-230.
35. Konoplev S, Medeiros LJ, Bueso-Ramos CE, Jorgensen JL, Lin P. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Am J Clin Pathol 2005;124:414-420.
36. Islam D, Lindberg AA, Christensson B. Peripheral blood cell preparation influences the level of expression of leukocyte cell surface markers as assessed with quantitative multicolor flow cytometry. Cytometry 1995;22:128-134.
37. Chuang SS, Huang WT, Hsieh PP, Teseng HH, Campo E, Colomer D, Ye H, Lu CL, Chang HM, Cho CY, Huang SH, Lu YC, Wu JD. Mantle cell lymphoma in Taiwan: Clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2. Pathol Int 2006;56:440-448.
38. Dyer MJS, Hale G, Hayhoe FGJ, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 1989;73:1431-1439.